Epizyme Archives -

News/ News/ News/ Oncology/ Sales and Marketing

Ipsen beefs up in oncology, buying US biopharma Epizyme

Phil Taylor Epizyme, Ipsen, M&A, Oncology, Tazverik 0 Comment

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its

Ipsen beefs up in oncology, buying US biopharma Epizyme

https://pharmaphorum.com/news/ipsen-beefs-up-in-oncology-buying-us-biopharma-epizyme/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Epizyme scores important follicular lymphoma approval with Tazverik

Richard Staines cancer, Epizyme, follicular lymphoma, R&D, Tazverik 0 Comment

Epizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in

Epizyme scores important follicular lymphoma approval with Tazverik

https://pharmaphorum.com/news/epizyme-unlocks-more-sales-with-tazverik-follicular-lymphoma-approval/

News/ News/ Oncology

FDA approves Epizyme’s Tazverik in sarcoma

Richard Staines cancer, Epizyme 0 Comment

The US regulator has approved Epizyme’s Tazverik (tazemetostat) for advanced sarcoma, providing a new option for a disease

FDA approves Epizyme’s Tazverik in sarcoma

https://pharmaphorum.com/news/fda-approves-epizymes-tazverik-in-sarcoma/

Healthcare/ Partner content/ Press releases

4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWERED

Natasha Boumediene Aurelia Bioscience, drug discovery, Epizyme, Novartis, TissUse 0 Comment

Drug Discovery Conference

4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWERED

https://pharmaphorum.com/partner-content/4-key-questions-in-new-experimental-technologies-answered/

Trending

Epizyme

Login